Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news...

Amgen (NASDAQ:AMGN) announced today that the FDA issued a priority (six-month) review for its Biologics License Application (BLA) for Denosumab (a subcutaneous RANK Ligand inhibitor) (bone protecting drug) seeking approval for reduction of skeletal related events (SREs) in patients with advanced cancer.

Roche (OTC:RHHBY) has a scheduled Oncologic Drugs FDA Advisory Committee meeting scheduled for tomorrow to review the previously issued accelerated approval for AVASTIN (bevacizumab) as a first-line treatment for HER2-negative breast cancer based on the results of required post-approval study data.

Below are summaries of the most recent articles written by Mark Messier at www.BioRunUp.com - please visit the site to read the full articles, in addition to many other free tools and strategies related to binary event investing...

Vivus (NASDAQ:VVUS) - What Now?

Jul 19th, 2010 by BioRunUp

With last week's majority "No" vote from the FDA, the questions can be asked- What now? Is VVUS dead? Those are excellent questions that biotech traders new and old are asking themselves.  Let's take a look at VVUS now, and put together a game plan for the next few months...

http://twitter.com/BioRunUp Working on a write-up for $CPIX. Got an email from Cumberland Pharma (NASDAQ:CPIX) IR dept- PDUFA for sNDA Acetadote is 9/10/10. Coming up fast. Added 2k. Why no PR??

www.mikehavRx.com is your prescription for stock index investing updates focused on the healthcare sector, medical innovation, and pending binary events such as FDA decisions and clinical trials. The HavRx Regulatory Catalyst Index update report is currently tracking 605 entries and 409 companies (with approximately 200 stocks trading under $5 per share and 66 private companies). Click here for a subscriber overview article that includes an email archive web link for a 50% discount ($150) promo code off the regular one-year, non-recurring subscription price.

Disclosure: No positions